CDC: Teenagers infected with HIV are not aware

Food Insecurity and the Dangers of Infant Formula Dilution

This week the panel weighs in on monoclonal antibodies in this patient population as well as important overall takeaways about COVID-19 therapies.

January 30th 2023

FDA approves first generic GLP-1 injection for type 2 diabetes in patients 10 years and up

Patrick Campbell

December 23rd 2024

Demystifying Infant Formula

The FDA has approved the first generic once-daily GLP-1 injection for the improvement of glycemic control for type 2 diabetes in patients 10 years and up.

October 11th 2022

FDA expands setmelanotide indication to patients as young as 2 years

FDA expands setmelanotide indication for patients as young as 2 years | Image Credit: © Calin - © Calin - stock.adobe.com.

Afrezza inhaled insulin meets primary endpoint in phase 3 pediatric diabetes trial

The expanded indication is approved to reduce excess body weight and maintain reduction long-term in children 2 years and up with obesity due to BBS, POMC, or LEPR deficiency.

COVID-19 Roundtable: Prophylaxis for the immunocompromised

The primary endpoint was non-inferiority in HbA1c levels after 26 weeks.

Related Content

Joshua Fitch, Senior Editor ;John Parkinson

December 24th 2024

Food Insecurity and the Dangers of Infant Formula Dilution

This week the panel weighs in on monoclonal antibodies in this patient population as well as important overall takeaways about COVID-19 therapies.

January 30th 2023

FDA approves first generic GLP-1 injection for type 2 diabetes in patients 10 years and up

Patrick Campbell

December 23rd 2024

Demystifying Infant Formula

The FDA has approved the first generic once-daily GLP-1 injection for the improvement of glycemic control for type 2 diabetes in patients 10 years and up.

October 11th 2022

FDA expands setmelanotide indication to patients as young as 2 years

Afrezza inhaled insulin meets primary endpoint in phase 3 pediatric diabetes trial

The expanded indication is approved to reduce excess body weight and maintain reduction long-term in children 2 years and up with obesity due to BBS, POMC, or LEPR deficiency.